
ADHD P/E Ratio
P/E Ratio as of Dec 4, 2025: -2.77
Average-2.97
Median-2.76
Minimum-3.92
Maximum-2.39
-2.77
1.25 (31.09%)past month
The P/E ratio for ADHD is -2.77 as of Dec 4, 2025. This represents a decrease of -51.06% compared to its 12-month average P/E ratio of -5.66. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Arcturus Therapeutics Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Arcturus Therapeutics Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Arcturus Therapeutics Ltd to industry peers.
Arcturus Therapeutics Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Arcturus Therapeutics Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Arcturus Therapeutics Ltd to industry peers.
ADHD P/E Ratio Insights
See Arcturus Therapeutics Ltd’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in ADHD
Order type
Buy in
Order amount
Est. shares
0 shares
ADHD P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $6.49 | -2.63 |
| Nov 3, 2025 | $9.30 | -4.18 |
| Oct 1, 2025 | $20.48 | -9.21 |
| Sep 2, 2025 | $16.70 | -7.51 |
| Aug 1, 2025 | $12.30 | -4.87 |
| Jul 1, 2025 | $12.99 | -5.15 |
| Jun 2, 2025 | $12.81 | -5.08 |
| May 1, 2025 | $12.50 | -4.16 |
| Apr 1, 2025 | $9.43 | -3.14 |
| Mar 3, 2025 | $15.68 | -7.09 |
| Feb 3, 2025 | $15.80 | -7.14 |
| Jan 2, 2025 | $17.07 | -7.71 |
ADHD End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -2.77 | -63.89% |
| 2024 | -7.67 | -187.96% |
| 2023 | 8.72 | -385.90% |
| 2022 | -3.05 | -36.19% |
| 2021 | -4.78 | -62.71% |
| 2020 | -12.82 | — |
FAQs About Arcturus Therapeutics Ltd (ADHD) P/E ratio
The latest P/E ratio of ADHD is -2.77, as of Dec 4, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Arcturus Therapeutics Ltd’s last 12-month average P/E ratio is -5.66, compared to its current P/E ratio of -2.77. This reflects a decrease of -51.06%.
Arcturus Therapeutics Ltd’s current P/E ratio of -2.77 is lower than its last 12-month average P/E of -5.66. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Arcturus Therapeutics Ltd’s average P/E ratio over the last 3 years is -0.5. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Arcturus Therapeutics Ltd’s average P/E ratio over the last 5 years is -2.82. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.